natgillin/translations-raw huggingface dataset:
Single components of the primary composite endpoint for the pharmaco-invasive strategy versus primary PCI respectively were observed with the following frequencies: 
Pogostnost posamičnih sestavin primarnega, sestavljenega opazovanega dogodka je bila pri farmakoinvazivni strategiji v primerjavi s primarno PKI naslednja:
With regard to the indication and the single dose administration in humans, reproductive toxicity testing was limited to an embryotoxicity study in rabbits, as a sensitive species. 
Glede na indikacijo in uporabo enkratnih odmerkov pri človeku so raziskave o toksičnih učinkih na reproduktivno funkcijo izvajali samo pri kuncih kot občutljivi živalski vrsti.
All-cause mortality Cardiogenic shock Congestive heart failure Re-infarction Cardiac mortality 
Kardiogeni šok Zastojno srčno popuščanje Ponovni infarkt Kardiološka umrljvost
Breast-feeding should be discarded within the first 24 hours after thrombolytic therapy. 
Prvih 24 ur po trombolitični terapiji je potrebno materino mleko zavreči.
Hypersensitivity/Re-administration 
Preobčutljivost/ponovno dajanje
However, for microbiological reasons your doctor will normally use the reconstituted solution for injection immediately. 
Vendar zdravnik pripravljeno raztopino za injiciranje zaradi mikrobioloških razlogov običajno uporabi takoj po pripravi.
Rare (may affect up to 1 in 1,000 people): Blood clot in the lung (pulmonary embolism) 
Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov):: krvni strdek v pljučih (pljučna embolija).
Medicinal products that affect coagulation or those that alter platelet function (e.g. ticlopidine, clopidogrel, LMWH) may increase the risk of bleeding prior to, during or after tenecteplase therapy. 
Zdravila, ki vplivajo na strjevanje krvi, in tista, ki spremenijo delovanje trombocitov (npr. tiklopidin, klopidogrel, nizkomolekularni heparin), lahko povečajo tveganje krvavitve pred zdravljenjem s tenekteplazo ter med njim in po njem.
Not known(frequency cannot be estimated from the available data): fat embolism (clots consisting of fat) nausea vomiting body temperature increased (fever) blood transfusions as consequence of bleedings 
Neznana(pogostnosti iz razpoložljivih podatkov ni mogoče oceniti): -maščobna embolija (maščobni strdki), -siljenje na bruhanje, -bruhanje, -povečanje telesne temperature (vročina), -krvne trensfuzije zaradi krvavitev.
It should not be administered in a line containing glucose. 
Ne smemo ga injicirati v venski kanal, v katerem je glukoza.
Other medicinesand Metalyse 
Druga zdravila inzdravilo Metalyse
The occurrence of the primary endpoint, a composite of death or cardiogenic shock or congestive heart failure within 90 days, was significantly higher in the group receiving the exploratory regimen of tenecteplase followed by routine immediate PCI: 18.6% (151/810) compared to 13.4% (110/819) in the PCI only group, p=0.0045. 
Pojavnost primarnega opazovanega dogodka, ki je bil sestavljen iz smrti ali kardiogenega šoka ali kongestivnega srčnega popuščanja v 90 dneh, je bila pomembno večja v skupini, ki je prejemala režim zdravljenja v preskušanju, to je tenekteplazo in nato rutinsko takojšnjo PKI: 18,6 % (151/810) v primerjavi s 13,4 % (110/819) v skupini, ki je prejemala samo PKI; p = 0,0045.
The reconstituted preparation is a clear and colourless to slightly yellow solution. 
Rekonstituirani pripravek je prozorna, brezbarvna do rumenkasta raztopina.
The bounds of the confidence interval of the observed incidences prior and after dose reduction are overlapping. 
Meje intervala zaupanja pri pojavnosti pred zmanjšanjem odmerka in po njem se prekrivajo.
Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis 
• hude motnje delovanja jeter, kot so jetrna odpoved, ciroza, portalna hipertenzija (varice v požiralniku) in aktivni hepatitis,
The reconstituted preparation results in a colourless to pale yellow, clear solution. 
Pripravek je brezbarvna do bledo rumena, prozorna raztopina.
Increasing body weight resulted in a moderate increase of tenecteplase clearance, and increasing age resulted in a slight decrease of clearance. 
Pri večji telesni masi je bil očistek tenekteplaze zmerno večji, pri večji starosti pa nekoliko manjši.
Tenecteplase is an intravenously administered, recombinant protein that activates plasminogen. 
Tenekteplaza je rekombinantni protein za intravensko uporabo, ki aktivira plazminogen.
Clinical data as well as nonclinical studies on fertility are not available for tenecteplase (Metalyse). 
Za tenekteplazo (zdravilo Metalyse) ni na voljo kliničnih podatkov ali nekliničnih raziskav o plodnosti.
If you get any side effects, talk to your doctor or nurse. 
Če opazite katerega koli izmedneželenih učinkov, se posvetujte z zdravnikom ali medicinsko sestro.
20 ml glass vial type I, with a coated (B2-42) grey rubber stopper and a flip-off cap filled with powder for solution for injection. 
Steklena viala tipa I po 20 ml z obloženim (B2-42) sivim gumijastim zamaškom in tesnilno zaporko, napolnjeno s praškom za raztopino za injiciranje.
See section 4. 
Glej tudi poglavje 4.4.
It is recommended that antiarrhythmic therapy for bradycardia and/or ventricular tachyarrhythmias (pacemaker, defibrillator) is available when tenecteplase is administered. 
Med dajanjem tenekteplaze je priporočljivo imeti pripravljeno opremo za odpravo bradikardije in/ali ventrikularnih tahiaritmij (srčni spodbujevalnik, defibrilator).
The following adverse events occurred more frequently with tenecteplase prior to PCI: intracranial haemorrhage: 1% vs. 0% p=0.0037; stroke: 1.8% vs. 0% p<0.0001; major bleeds: 5.6% vs. 4.4% p=0.3118; minor bleeds: 25.3% vs. 19.0% p= 0.0021; blood transfusions: 6.2% vs. 4.2% p=0.0873; abrupt vessel closure: 1.9% vs. 0.1% p=0.0001. 
Naslednji neželeni dogodki so bili pogostnejši pri dajanju tenekteplaze pred PKI: intrakranialna krvavitev: 1 % glede na 0 %, p = 0,0037; kap: 1,8 % glede na 0 %, p < 0,0001; večje krvavitve: 5,6 % glede na 4,4 %, p = 0,3118; manjše krvavitve: 25,3 % glede na 19,0 %, p = 0,00021; krvne transfuzije: 6,2 % glede na 4,2 %, p = 0,0873; nenadno zaprtje žile: 1,9 % glede na 0,1 %, p = 0,0001.
In patients ≥ 75 years the observed incidence of the primary efficacy composite end point for the pharmaco-invasive strategy and primary PCI were as follows: before dose reduction 11/37 (29.7%) (95% CI: 15.9- 47.0) versus 10/32 (31.3%) (95% CI: 16.1-50.0), after dose reduction: 25/97 (25.8%) (95% CI: 17.4-35.7) versus 25/88 (24.8%) (95% CI: 19.3-39.0). 
Pri bolnikih, starih ≥ 75 let, je bila pojavnost primarnega učinkovitostnega sestavljenega opazovanega dogodka pri farmakoinvazivni strategiji in primarni perkutani koronarni intervenciji naslednja: pred zmanjšanjem odmerka 11/37 (29,7 %) (95-odstotni IZ: 15,9-47,0) v primerjavi z 10/32 (31,3 %) (95-odstotni IZ: 16,1-50,0) po zmanjšanju odmerka: 25/97 (25,8 %) (95-odstotni IZ: 17,4-35,7) v primerjavi s 25/88 (24,8 %) (95-odstotni IZ: 19,3-39,0).
Uncommon (may affect up to 1 in 100 people): irregular heart beat (reperfusion arrhythmias), sometimes leading to cardiac arrest. 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov): neredno bitje srca (reperfuzijske aritmije), ki lahko povzroči srčni zastoj.
A target fibrinogen level of 1 g/l is desirable with cryoprecipitate infusion. 
Z infuzijo krioprecipitata poskušamo doseči ciljno raven fibrinogena 1 g/l.
Before use, the solvent (water for injections) is added to the powder to form a solution that is given by injection. 
Pred uporabo dodamo prašku vehikel (vodo za injekcije) in tako pripravimo raztopino, ki jo dajemo z injekcijo.
In the event of overdose there may be an increased risk of bleeding. 
Prevelik odmerek poveča nevarnost krvavitve.
Numerically all of the components of the clinical composite endpoint were in favour of the PCI only regimen: death: 6.7% vs. 4.9% p=0.14; cardiogenic shock: 6.3% vs. 4.8% p=0.19; congestive heart failure: 12.0% vs. 9.2% p=0.06 respectively. 
Številčno so bile vse sestavine kliničnega sestavljenega opazovanega dogodka v prid režimu zdravljenja s samo PKI: smrt: 6,7 % glede na 4,9 %, p = 0,14; kardiogeni šok : 6,3 % glede na 4,8 %, p = 0,19 ; kongestivno srčno popuščanje: 12,0 % glede na 9,2 %, p = 0,06.
Binding to hepatic receptors is, however, reduced compared to native tPA, resulting in a prolonged half-life. 
Vezava na receptorje v jetrih pa je manjša kot pri naravnem t-PA, zato je razpolovna doba daljša.
Administration of protamine should be considered if heparin has been administered within 4 hours before the onset of bleeding. 
Če je bolnik prejel heparin v 4 urah pred krvavitvijo, je treba presoditi o dajanju protamina.
After single intravenous bolus injection of tenecteplase in patients with acute myocardial infarction, tenecteplase antigen exhibits biphasic elimination from plasma. 
Po enkratni bolusni injekciji tenekteplaze se pri bolnikih z akutnim miokardnim infarktom antigen tenekteplaze iz plazme izloča v dveh fazah.
Tenecteplase is a recombinant fibrin-specific plasminogen activator that is derived from native t-PA by modifications at three sites of the protein structure. 
Tenekteplaza je rekombinantni, za fibrin specifični aktivator plazminogena, pridobljen iz naravnega tkivnega aktivatorja plazminogena (t-PA) z modifikacijami proteinske strukture na treh mestih.
Caution is needed when administering tenecteplase to persons with a known hypersensitivity (other than anaphylactic reaction) to the active substance, to any of the excipients, or to gentamicin (a residue from the manufacturing process). 
Tenekteplazo je treba previdno dajati osebam z znano preobčutljivostjo (poleg anafilaktične reakcije) za zdravilno učinkovino, katerokoli pomožno snov ali gentamicin (ostanek v sledeh iz proizvodnega postopka).
if you have had any allergic reaction other than a sudden life-threatening allergic reaction (severe hypersensitive) to the active substance tenecteplase, to gentamicin (a trace residue from the manufacturing process), or to any of the other ingredients of Metalyse (see section 6: “Contents of the pack and other information”); if you have high blood pressure; if you have problems with circulation of blood in the brain (cerebrovascular disease); if you have had gastrointestinal (gut) or genitourinary bleeding within the last ten days (this may cause blood in stools or urine); if you have a heart valve abnormality (e.g. mitral stenosis) with an abnormal heart rhythm (e.g. atrial fibrillation); if you have had an intramuscular injection in the last two days; if you are aged over 75 years; if you weigh less than 60 kg; if you have ever received Metalyse before. 
Na kaj bo zdravnik posebno pozoren pri uporabi zdravila Metalyse če ste že imeli kakršnokoli alergijsko reakcijo na učinkovino tenekteplazo, gentamicin (ostanek v sledeh iz proizvodnega postopka) ali keterokoli drugo sestavino zdravila Metalyse, razen nenadne življenjsko nevarne alergijske reakcije (hude preobčutljivosti) (glejte poglavje 6: Vsebina pakiranja in dodatne informacije); če imate visok krvni tlak; če imate motnje obtoka krvi v možganih (cerebrovaskularno bolezen); če ste imeli v preteklih desetih dneh krvavitev v prebavilih (črevesju), rodilih ali sečilih (v njih se lahko pojavi kri v blatu ali seču); če imate nepravilnost srčne zaklopke (npr. mitralno stenozo) in nenormalen srčni ritem (npr. fibrilacijo preddvorov); če ste v preteklih dveh dneh prejeli injekcijo v mišico; če ste starejši od 75 let; če ste lažji od 60 kg, če ste kadar koli že prejeli zdravilo Metalyse.
Transfer the appropriate volume of reconstituted solution of Metalyse into the syringe, based on the patient's weight. 
V brizgo prenesemo ustrezen volumen pripravljene raztopine zdravila Metalyse, določen glede na bolnikovo telesno maso.
The type of haemorrhage is predominantly superficial at the injection site. 
Večinoma se pojavi kot površinska krvavitev na mestu injekcije.
If treatment with Metalyse is nevertheless considered to be necessary, facilities for resuscitation should be immediately available in case of need. 
6e je zdravljenje z zdravilom Metalyse kljub temu potrebno, mora biti za takojšnjo uporabo na voljo oprema za oživljanje.
Volume of reconstituted solution (ml) 
Volumen pripravljene raztopine (ml)
Then immediately screw the pre-filled syringe on the vial adapter and penetrate the vial stopper in the middle with the spike of the vial adapter. 
Nato napolnjeno brizgo takoj privijemo na nastavek za vialo in zamašek viale v sredini prebodemo s konico nastavka za vialo.
Add the water for injections by pushing the syringe plunger slowly down to avoid foaming. 
Dodamo vodo za injekcije, tako da brizgin bat počasi potisnemo navzdol, da preprečimo penjenje.
The primary endpoint, a composite of death or cardiogenic shock or congestive heart failure or re-infarction within 30 days, was observed in 12.4% (116/939) of the pharmaco-invasive arm versus 14.3% (135/943) in the primary PCI arm (relative risk 0.86 (0.68-1.09)). 
Pogostnost primarnega sestavljenega opazovanega dogodka, ki je zajemal smrt ali kardiogeni šok ali zastojno srčno popuščanje ali ponovni infarkt v 30 dneh, je bila v skupini s farmakoinvazivno strategijo 12,4 % (116/939), v skupini s primarno perkutano koronarno intervencijo pa 14,3 % (135/943) (relativno tveganje 0,86 (0,68-1,09)).
The safety and efficacy of Metalyse in children (below 18 years) have not been established. 
Varnost in učinkovitost zdravila Metalyse pri otrocih, starih do 18 let, nista bili dokazani.
The secondary endpoints re-infarction and repeat target vessel revascularisation were significantly increased in the group pre-treated with tenecteplase: reinfarction: 6.1% vs. 3.7% p=0.0279; repeat target vessel revascularisation: 6.6% vs. 3.4% p=0.0041. 
Pogostnost sekundarnih opazovanih dogodkov, ponovnega infarkta in ponovne revaskularizacije tarčne žile se je v skupini s predzdravljenjem s tenekteplazo pomembno povečala: ponovni infarkt: 6,1 % glede na 3,7 %, p = 0,0279; ponovna revaskularizacija tarčne žile: 6,6 % glede na 3,4 %, p = 0,0041.
Excipients: L-Arginine, Phosphoric Acid, Polysorbate 20 Trace residue from manufacturing process: Gentamicin The solvent is water for injections. 
L-arginin fosforjeva kislina polisorbat 20 ostanek v sledeh iz proizvodnega postopka: gentamicin Vehikel voda za injekcije
The observed incidence of major and of minor non-ICH bleeds were similar in both groups: Pharmaco-invasive (n=944) 
Pojavnost velikih in manjših neintrakranialnih krvavitev je bila v obeh skupinah podobna
Intracranial haemorrhage (such as cerebral haemorrhage, cerebral haematoma, haemorrhagic stroke, haemorrhagic transformation stroke, intracranial haematoma, subarachnoid haemorrhage) including associated symptoms as somnolence, aphasia, hemiparesis, convulsion 
Bolezni živčevja občasni intrakranialna krvavitev (na primer možganska krvavitev, možganski hematom, hemoragična možganska kap, hemoragična transformacija kapi, intrakranialni hematom, subarahnoidna krvavitev), tudi povezani simptomi, kot so zaspanost, afazija, hemipareza, konvulzija
For intravenous use after reconstitution with 10 ml solvent 
Za intravensko uporabo po pripravi z 10 ml vehikla
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 8 ml water for injections 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 8 ml vode za injekcije
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 10 ml water for injections 
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT 10 ml vode za injekcije
For intravenous use after reconstitution with 8 ml solvent 
Za intravensko uporabo po pripravi z 8 ml vehikla
The benefit of treatment must be evaluated against the potential risks in case of myocardial infarction during pregnancy. 
V primeru miokardnega infarkta med nosečnostjo je treba o koristi zdravljenja presoditi glede na možno tveganje.
This leaflet was last approved in {MM/YYYY}. 
Navodilo je bilo nazadnje revidirano dne {MM/LLLL} Drugi viri informacij
The active substance is tenecteplase. 
Učinkovina je tenekteplaza.
Skin and subcutaneous tissue disorders Common 
Bolezni kože in podkožja pogosti ekhimoza
1 vial of powder for solution for injection with 50 mg tenecteplase 1 pre-filled syringe with 10 ml of solvent for parenteral use 
1 viala praška za raztopino za injiciranje s 50 mg tenekteplaze 1 napolnjena injekcijska brizga z 10 ml vehikla za parenteralno uporabo
Now solution is ready for iv. bolus injection. 
Raztopina je sedaj pripravljena za bolusno injekcijo.
Any known history of haemorrhagic stroke or stroke of unknown origin Known history of ischaemic stroke or transient ischaemic attack in the preceding 6 months Dementia 
• znana anamneza ishemične kapi ali prehodne ishemične napade v preteklih 6 mesecih,
Add the water for injections into the vial by pushing the syringe plunger down slowly to avoid foaming. 
V vialo dodamo vodo za injekcije, tako da brizgin bat počasi potisnemo navzdol, da preprečimo penjenje.
Intracranial haemorrhage occurred at a rate of 0.93% vs. 0.94% for tenecteplase and alteplase, respectively. 
Pogostnost možganskih krvavitev je bila 0,93 % med zdravljenjem s tenekteplazo in 0,94 % med zdravljenjem z alteplazo.
Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) 
• poškodba osrednjega živčnega sistema v anamnezi (npr. novotvorba, anevrizma, operacija na možganih ali hrbtenici),
Check that the cap of the vial is still intact. 
Pregledamo, ali je vialina zaporka nepoškodovana.
As with other thrombolytic agents, the following events have been reported as sequelae of myocardial infarction and/or thrombolytic administration: - very common: hypotension, heart rate and rhythm disorders, angina pectoris - common: recurrent ischaemia, cardiac failure, myocardial infarction, cardiogenic shock, 
Enako kot za druga trombolitična zdravila navajajo poročila naslednje dogodke, ki so bili posledica miokardnega infarkta ali zdravljenja s trombolitičnim zdravilom ali obeh: - zelo pogosti: hipotenzija, motnje srčne frekvence in srčnega ritma, angina pektoris,
The most common complication encountered during tenecteplase therapy is bleeding. 
Med zdravljenjem s tenekteplazo je najpogostnejši zaplet krvavitev.
Metalyse must not be administered to patients with a history of an anaphylactic (i.e. life-threatening) reaction to any of the constituents (i.e. tenecteplase or any excipient) or gentamicin (a trace residue from the manufacturing process). 
Zdravila Metalyse ne smemo dajati bolnikom, ki imajo v anamnezi anafilakti6no (življenjsko nevarno) reakcijo na katerokoli sestavino (tenekteplazo ali katerokoli pomožno snov) ali gentamicin (ostanek v sledeh iz proizvodnega postopka).
The reconstituted solution contains 1,000 units (5 mg) tenecteplase per ml. 
Pripravljena raztopina vsebuje 1.000 enot (5 mg) tenekteplaze v 1 ml.
The carton contains one vial with a lyophilised powder with 50 mg tenecteplase, one ready for use pre-filled syringe with 10 ml solvent, one vial adapter and one needle. 
Škatla vsebuje eno vialo z liofiliziranim praškom s 50 mg tenekteplaze, eno napolnjeno brizgo z 10 ml vehikla, pripravljeno za uporabo, en adapter za vialo in eno iglo.
Death and permanent disability are reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes. 
Pri bolnikih s kapjo (tudi možgansko krvavitvijo) in drugimi resnimi krvavitvami poročajo o smrtnem izidu in trajni invalidnosti.
The carton contains one vial with a lyophilised powder with 40 mg tenecteplase, one ready for use pre-filled syringe with 8 ml solvent, one vial adapter and one needle. 
Škatla vsebuje eno vialo z liofiliziranim praškom s 40 mg tenekteplaze, eno napolnjeno brizgo z 8 ml vehikla, pripravljeno za uporabo, en adapter za vialo in eno iglo.
The concomitant use of heparin anticoagulation may contribute to bleeding. 
Sočasno dajanje heparina lahko poveča nevarnost krvavitve.
Metalyse should be reconstituted by adding the complete volume of water for injections from the prefilled syringe to the vial containing the powder for injection. 
6.6 Posebni varnostni ukrepi za odstranjevanje in ravnanje z zdravilom Zdravilo Metalyse moramo pripraviti tako, da dodamo ves volumen vode za injekcije iz napolnjene brizge v vialo s praškom za injiciranje.
a bleeding disorder or tendency to bleed (haemorrhage) stroke (cerebrovascular event) very high, uncontrolled blood pressure a head injury severe liver disease a stomach ulcer (peptic ulcer) varicose veins in the gullet (oesophageal varices) abnormality of the blood vessels (e.g. an aneurysm) certain tumours inflammation of the lining around the heart (pericarditis); inflammation or infection of the heart valves (endocarditis) dementia; 
zelo visok nenadzorovan krvni tlak, poškodbo glave, hudo jetrno bolezen, želodčno razjedo (peptični ulkus), varikozne vene v predelu požiralnika, nepravilnosti krvnih žil (npr. anevrizmo), nekatere vrste tumorjev, vnetje osrčnika (perikarditis); vnetje ali okužbo srčnih zaklopk (endokarditis), demenco;
Antithrombotic adjunctive therapy with platelet inhibitors and anticoagulants should be administered according to the current relevant treatment guidelines for the management of patients with ST-elevation myocardial infarction. 
Protitrombotično dodatno zdravljenje z zaviralci trombocitov in antikoagulansi mora biti v skladu z veljavnimi smernicami za zdravljenje bolnikov z miokardnim infarktom in elevacijo spojnice ST. Za koronarne intervencije glejte poglavje 4.4.
Penetrate the vial stopper in the middle with the spike of the vialadapter. 
Zamašek viale v sredini prebodemo s konico nastavka za vialo.
one vial of 8,000 units Metalyse powder and one pre-filled syringe containing 8 ml water for injections 
- eno vialo z 8.000 enotami praška zdravila Metalyse in - eno napolnjeno brizgo z 8 ml vode za injekcije.
Patients receiving oral anticoagulants: The use of Metalyse may be considered when dosing or time since the last intake of anticoagulant treatment makes residual efficacy unlikely and if appropriate test(s) of anticoagulant activity for the product(s) concerned show no clinically relevant activity on the coagulation system (e.g. INR ≤ 1.3 for vitamin K antagonists or other relevant test(s) for other oral anticoagulants are within the respective upper limit of normal). 
ko zaradi odmerjanja antikoagulanta ali časa po njegovem zadnjem odmerku ni verjetno, da bi še trajal njegov rezidualni učinek, in če ustrezni preizkus/(i) antikoagulacijske aktivnosti za zadevno/(a) zdravilo/(a) ne pokaže/(jo) klinično pomembne aktivnosti na koagulacijski sistem
As with other thrombolytic agents, the following events have been reported as sequelae of myocardial infarction and/or thrombolytic administration: 
Tako kot pri drugih trombolitikih so poročali o naslednjih dogodkih, ki so bili posledica miokardnega infarkta ali dajanja trombolitika:
Rare(may affect up to 1 in 1,000 people): low blood pressure (hypotension) bleeding in the lungs (pulmonary haemorrhage) hypersensitivity (anaphylactoid reactions) e.g. rash, hives (urticaria), difficulty breathing (bronchospasm) bleeding into the area surrounding the heart (haemopericardium) blood clot in the lung (pulmonary embolism)and in the vessels of other organ systems (thrombotic embolisation) 
Redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov): - nizek krvni tlak (hipotenzija), - krvavitev v pljučih (pljučna hemoragija), - preobčutljivost (anafilaktoidne reakcije) npr. izpuščaj, koprivnica (urtikarija), težave z dihanjem (bronhospazem), krvavitev v osrčnik (hemoperikardij), krvni strdek v pljučih (pljučna embolija)in žilah drugih organskih sistemov (trombotična embolija).
Data on the foetal period are not available. 
O plodovem razvoju ni na voljo podatkov.
Sterile vial adapter. 
Sterilni nastavek za vialo.
Boehringer Ingelheim Pharma GmbH & Co. KG Birkendorfer Strasse 65, 88397 Biberach/Riss Germany 
KG Birkendorfer Strasse 65, 88397 Biberach/Riss Nemčija